Global Cell And Gene Therapy Clinical Trials Market Size study, by Phase (Phase I, II, III, IV), By Indication (Oncology, CNS, Cardiology, Musculoskeletal, Infectious Diseases, Dermatology, Others)and Regional Forecasts 2022-2028

Global Cell And Gene Therapy Clinical Trials Market Size study, by Phase (Phase I, II, III, IV), By Indication (Oncology, CNS, Cardiology, Musculoskeletal, Infectious Diseases, Dermatology, Others)and Regional Forecasts 2022-2028

Global Cell And Gene Therapy Clinical Trials Market is valued approximately USD 7.3 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 14.6 % over the forecast period 2022-2028. The rise in R&D investment, increased patient demand for new therapeutics, and expanding interest in cell and gene therapies for cancer therapy are driving the market. Cell and gene therapy (CGT) is a new frontier in the treatment of many severe illnesses, including uncommon genetic abnormalities and malignancies. It symbolizes a new era of innovation in the life sciences business. The COVID-19 pandemic decreased the number of gene therapy clinical trials in the early 2020s since most research was aimed at treating and diagnosing COVID-19. According to world Health Organization,, the percentage of gene therapy clinical studies grew dramatically in 2021 compared to previous years, as many researchers are now devoting their emphasis to gene therapy because of its promise in treating cancer and other uncommon disorders. This trend is projected to increase market growth over the next several years. CGT medicines had an R&D success rate of 11 percent from Phase I to commercialization between 2008 and 2018, compared to 8.2 percent for small-molecule compounds. The quantity and sophistication of the enterprises entering the market are expanding significantly. Small biotech businesses were among the early movers in this field. There was a lot of interest in the main biopharma companies. The vast majority of multinational pharmaceutical corporations are currently investing in CGT. For example, Novartis said in December 2021 that it had reached an acquisition deal with Gyroscope Therapeutics, an eye gene therapy business. However, stringent compliance regulations limit market growth over the projection period of 2022-2028.

The key regions considered for the Global Cell And Gene Therapy Clinical Trials Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America emerged as the market leader. This is due to a favourable regulatory environment, particularly in the United States. The FDA in the United States has designed a collaborative regulatory method for CGTs that includes early and consistent involvement with the sponsor, as well as unique regulatory designations that are useful for many CGTs. Furthermore, the regulatory clearance procedure in the United States is improving and becoming more beneficial to vendors producing CGT goods. During the projection period, Asia Pacific is expected to grow at the quickest CAGR. On the Asia Pacific area, a growing number of biotechnology enterprises are focusing in regenerative therapies. Furthermore, with the continued expansion of medical tourism destinations such as Thailand, Singapore, and India, the area is expected to maintain its position as the core of cell research and therapy.

Major market player included in this report are:
IQVIA
ICON Plc
Laboratory Corporation of America Holdings
Charles River Laboratories International, Inc
PAREXEL International Corp.
Syneos Health
Medpace Holdings, Inc.
PPD Inc.
Novotech
Veristat, LLC
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Phase:
Phase I
Phase II
Phase III
Phase IV
By Indication:
Oncology
CNS
Cardiology
Musculoskeletal
Infectious Diseases
Dermatology
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Cell And Gene Therapy Clinical Trials Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

IQVIA
ICON Plc
Laboratory Corporation of America Holdings
Charles River Laboratories International, Inc
PAREXEL International Corp.
Syneos Health
Medpace Holdings, Inc.
PPD Inc.
Novotech
Veristat, LLC

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.